Background
==========

Delirium is a common occurrence in critically ill patients and is associated with an increase in morbidity and mortality \[[@B1]\]. Some evidence suggests that septic patients with delirium may differ from a general critically ill population. In a subgroup analysis of the MENDS study, a benefit of dexmedetomidine sedation over lorazepam was only evident in septic patients \[[@B2]\]. The aim of our study was investigate the relationship between systemic inflammation and the development of delirium in septic and nonseptic critically ill patients.

Materials and methods
=====================

We performed a cohort study in a 20-bed mixed ICU that included consecutive patients admitted for more than 24 hours. Delirium was diagnosed using the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). Coma was defined as a Richmond Agitation Sedation Scale (RASS) score of -4 or -5. Blood samples were collected within 12 hours of enrollment for determination of TNFα, soluble TNF receptor (STNFR)-1 and STNFR-2, IL-1β, IL-6, IL-10 and adiponectin.

Results
=======

Seventy-eight patients were included in the study: 26 nonseptic/nondelirium (control), 13 nonseptic/delirium (delirium), 21 septic/nondelirium (septic) and 18 septic/delirium (sepsis-associated delirium (SAD)). From all analyzed biomarkers only STNFR1, STNFR2 and adiponectin were independently associated with delirium occurrence, but none of these biomarkers had a significant interaction with sepsis. In contrast, there was significantly interaction between sepsis and IL-1β suggesting that this cytokine is differently modulated when comparing septic and nonseptic patients with delirium.

Conclusions
===========

The association between IL-1β and delirium is different in septic versus nonseptic patients, suggesting that mechanisms which drive SAD may differ from that of nonseptic ICU delirium.
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